Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | BCHE | P06276 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.60 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.59 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.58 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.55 |
| ▸ | TYR | P14679 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27762381 | 1.00 | NPC1 (0.63) | NPC1MAPTRAB9ALMNABCHE | |
| SCHEMBL27923020 | 0.92 | NPC1 (0.63) | NPC1MAPTRAB9ALMNABCHE | |
| SCHEMBL28126221 | 0.89 | NPC1 (0.63) | NPC1MAPTRAB9ALMNABCHE | |
| SCHEMBL4864059 | 0.89 | NPC1 (0.67) | NPC1MAPTRAB9ALMNABCHE | |
| SCHEMBL20608556 | 0.88 | BCHE (0.57) | NPC1MAPTRAB9ALMNABCHE | |
| SCHEMBL27702561 | 0.86 | MAPT (0.67) | NPC1MAPTRAB9ALMNABCHE | |
| SCHEMBL27741903 | 0.85 | ABCG2 (0.68) | NPC1MAPTRAB9ALMNABCHE | |
| SCHEMBL27741904 | 0.85 | ABCG2 (0.68) | NPC1MAPTRAB9ALMNABCHE | |
| SCHEMBL28557188 | 0.85 | BCHE (0.57) | NPC1MAPTRAB9ALMNABCHE | |
| SCHEMBL27391382 | 0.84 | NPC1 (0.60) | NPC1MAPTRAB9ALMNABCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1803809-A2 | Modulation of peroxisome proliferator-activated receptors | Abgenomics Corporation (TW) | 2007-07-04 | — | — | EP | claimed |
| US-20070037193-A1 | Modulation of peroxisome proliferator-activated receptors | ABGENOMICS CORPORATION (TW) | 2007-02-15 | — | — | US | claimed |
| CN-101448551-A | Use of chalcones for the treatment of viral disorders | JOHNSON & JOHNSON CONSUMER (US) | 2009-06-03 | — | — | CN | disclosed |
| EP-1803809-A2 | Modulation of peroxisome proliferator-activated receptors | Abgenomics Corporation (TW) | 2007-07-04 | — | — | EP | disclosed |
| US-20070037193-A1 | Modulation of peroxisome proliferator-activated receptors | ABGENOMICS CORPORATION (TW) | 2007-02-15 | — | — | US | disclosed |
| EP-0915864-A1 | GASTROPROTECTIVE FLAVONE/FLAVANONE COMPOUNDS WITH THERAPEUTIC EFFECT ON INFLAMMATORY BOWEL DISEASE | Dong A Pharmaceutical Co. Ltd. (KR) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998004541-A1 | GASTROPROTECTIVE FLAVONE/FLAVANONE COMPOUNDS WITH THERAPEUTIC EFFECT ON INFLAMMATORY BOWEL DISEASE | DONG A PHARMACEUTICAL CO., LTD. (KR) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037193-A1 | Modulation of peroxisome proliferator-activated receptors | PPARG, PPARA, PPARD | NPC1 843/4885MAPT 4229/4885RAB9A 3867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.